Rokos Capital Management LLP Intellia Therapeutics, Inc. Transaction History

Rokos Capital Management LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.02 - $27.22 $6.46 Million - $8.78 Million	-322,657 Reduced 22.04%	1,140,973 $25.5 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $1.72 Million - $2.4 Million	74,334 Added 5.35%	1,463,630 $44.6 Million
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $18.8 Million - $25.2 Million	563,233 Added 68.18%	1,389,296 $51.8 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $17.8 Million - $33.6 Million	535,535 Added 184.33%	826,063 $28.8 Million
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $2.26 Million - $3 Million	-41,856 Reduced 12.59%	290,528 $16.7 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $8.5 Million - $16.8 Million	220,869 Added 198.06%	332,384 $16.8 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $6.5 Million - $13.3 Million	111,515 New	111,515 $8.08 Million

317

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $835M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Rokos Capital Management LLP, based on Form 13F filings with the SEC.

Stay updated on Rokos Capital Management LLP with notifications on news.